Abstract
No public abstract is available from the verified source records.
Hamda Khan, Minhal Abidi, Safia Habib, Arbab Husain, Afreen Khanam, Mohd Mustafa, Moinuddin
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
LAG-3 as the third checkpoint inhibitor
10.1038/s41590-023-01569-z · 2023
Preclinical development in radiopharmaceutical therapy for prostate cancer
10.1053/j.semnuclmed.2023.06.007 · 2023
CAR-T cell combination therapy: the next revolution in cancer treatment
10.1186/s12935-022-02778-6 · 2022
Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions
10.3389/fimmu.2025.1647066 · 2025
Unresolved referenced work
Kept as external metadata until matched
Recent advances in non-small cell lung cancer targeted therapy; an update review
10.1186/s12935-023-02990-y · 2023
Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies
10.3390/cancers17020282 · 2025
Recent advances and remaining challenges in lung cancer therapy
10.1097/cm9.0000000000002991 · 2024
Coinhibitory pathways in immunotherapy for cancer
10.1146/annurev-immunol-032414-112049 · 2016
Monoclonal antibodies in breast cancer: a critical appraisal
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
10.1016/j.critrevonc.2023.103915 · 2023
PD-L1 Glycosylation and its impact on binding to clinical antibodies
10.1021/acs.jproteome.0c00521 · 2021
Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
10.1073/pnas.1811067116 · 2019
Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer
10.1136/jitc-2023-007336 · 2023
Surface glycan targeting for cancer nano-immunotherapy
10.1016/j.jconrel.2022.01.004 · 2022
Cytokines in the treatment of cancer
10.1089/jir.2018.0019 · 2019
Advanced glycation end products in diabetes, cancer and phytochemical therapy
10.1016/j.drudis.2020.07.003 · 2020
Determinants of the efficacy of viro-immunotherapy: a review
10.1016/j.cytogfr.2020.07.001 · 2020
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
10.4161/mabs.28965 · 2014
10.1016/j.semcancer.2017.10.003
10.1016/j.semcancer.2017.10.003 · 2018
Mechanism of action of immunotherapy
10.1053/j.seminoncol.2014.09.004 · 2014
The tale of TILs in breast cancer: a report from the international immuno-oncology biomarker working group
10.1038/s41523-021-00346-1 · 2021
Progress in research on cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and bladder cancer
10.32948/auo.2019.01.22 · 2019
Immunotherapy for head and neck cancer: present and future
10.1016/j.critrevonc.2022.103679 · 2022
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer
10.1097/ppo.0b013e3181eacbc4 · 2010
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
10.1038/s41591-018-0010-1 · 2018
Immunotherapy in melanoma: recent advances and future directions
10.1016/j.ejso.2016.07.145 · 2017
HMGB1 expression levels correlate with response to immunotherapy in non-small cell lung cancer
2024
RAGE-mediated inflammation in patients with septic shock
10.1016/j.jss.2016.01.019 · 2016
CTLA-4: From mechanism to autoimmune therapy
10.1016/j.intimp.2020.106221 · 2020
The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
10.3389/fimmu.2022.956090 · 2022
VIRO-immune therapy: a new strategy for treatment of pancreatic cancer
10.3748/wjg.v22.i2.748 · 2016
Emerging new therapeutic antibody derivatives for cancer treatment
10.1038/s41392-021-00868-x · 2022
Immunomodulatory effects of carbohydrates and advanced glycation end products
10.5897/bmbr2014-0237 · 2015
Cell therapy with TILs: training and taming T cells to fight cancer
10.3389/fimmu.2021.690499 · 2021
Regulation of PD-L1 glycosylation and advances in cancer immunotherapy
10.1016/j.canlet.2025.217498 · 2025
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
2016
Regulatory mechanisms of PD-1/PD-L1 in cancers
10.1186/s12943-024-02023-w · 2024
Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody
10.1016/j.ijpharm.2022.121969 · 2022
Role of receptor for advanced glycation end products in the complication and progression of various types of cancers
10.1016/j.bbagen.2015.05.020 · 2015
Recent clinical researches and technological development in TIL therapy
10.1007/s00262-024-03793-4 · 2024
Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry
10.4161/mabs.36313 · doi-reference
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
10.1186/s12943-025-02305-x · doi-reference
Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas
10.3389/fimmu.2021.721830 · doi-reference
Monoclonal antibodies in cancer therapy
10.3390/antib9030034 · doi-reference
Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges
10.1016/j.ctrv.2023.102520 · doi-reference
Altered glycosylation in cancer: molecular functions and therapeutic potential
10.1002/cac2.12610 · doi-reference
Exosome-based immunotherapy: a promising approach for cancer treatment
10.1186/s12943-020-01278-3 · doi-reference
Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer
10.1080/10717544.2022.2120566 · doi-reference
Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future
10.1158/1078-0432.ccr-22-1922 · doi-reference
Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer
10.1002/ctm2.901 · doi-reference
Immunogenicity of CAR T cells in cancer therapy
10.1038/s41571-021-00476-2 · doi-reference
The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer
10.1016/j.ctrv.2022.102500 · doi-reference
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma
10.1007/s12032-018-1080-0 · doi-reference
Immunomodulation by processed animal feed: the role of maillard reaction products and advanced glycation end-products (AGEs)
10.3389/fimmu.2018.02088 · doi-reference
CTLA-4 blockade: therapeutic potential in cancer treatments
10.2147/ott.s4833 · doi-reference
Bispecific antibodies in cancer therapy: target selection and regulatory requirements
10.1016/j.apsb.2023.05.023 · doi-reference
Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications
10.3389/fimmu.2022.947648 · doi-reference
Targeted cancer therapies: clinical pearls for primary care
10.46747/cfp.6807515 · doi-reference
PD-L1 and PD-1 in immune regulation and their implications in blood cancers
10.1016/j.adcanc.2024.100125 · doi-reference
Immune checkpoint inhibitors in cancer therapy
10.3390/curroncol29050247 · doi-reference
Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy
10.1136/jitc-2020-002086 · doi-reference
Advanced glycation end-products acting as immunomodulators for chronic inflammation, inflammaging and carcinogenesis in patients with diabetes and immune-related diseases
10.3390/biomedicines12081699 · doi-reference
Immunotherapy and targeted therapy—the new roadmap in cancer treatment
10.21037/atm.2019.05.58 · doi-reference
Role of advanced glycation end products in carcinogenesis and their therapeutic implications
10.2174/1381612825666190130145549 · doi-reference
Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer
10.1038/s41598-023-44211-6 · doi-reference
Harnessing cytokines and chemokines for cancer therapy
10.1038/s41571-021-00588-9 · doi-reference
Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy
10.1136/jitc-2025-012391 · doi-reference
Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer
10.1080/2162402x.2021.1874159 · doi-reference
Cytokines in cancer therapy
10.1016/s0165-2478(00)00247-9 · doi-reference
Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations
10.1053/j.seminoncol.2016.06.008 · doi-reference
Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy
10.3389/fimmu.2022.1038226 · doi-reference
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
10.1016/j.molmed.2014.10.009 · doi-reference
Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?
10.1038/ncponc0666 · doi-reference
CAR T-cells for cancer therapy
10.1080/02648725.2018.1430465 · doi-reference
Engineering-enhanced CAR T cells for improved cancer therapy
10.1038/s43018-021-00241-5 · doi-reference
Recent clinical researches and technological development in TIL therapy
10.1007/s00262-024-03793-4 · doi-reference
Role of receptor for advanced glycation end products in the complication and progression of various types of cancers
10.1016/j.bbagen.2015.05.020 · doi-reference
Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody
10.1016/j.ijpharm.2022.121969 · doi-reference
Regulatory mechanisms of PD-1/PD-L1 in cancers
10.1186/s12943-024-02023-w · doi-reference
Regulation of PD-L1 glycosylation and advances in cancer immunotherapy
10.1016/j.canlet.2025.217498 · doi-reference